Karyopharm Therapeutics Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Richard A. Paulson
- Full Time Employees
- 228
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 85 Wells Avenue Newton MA United States of America 02459-3298
- IPO Date
- Nov 6, 2013
- CIK
- 0001503802
- Website
- karyopharm.com
- Similar Companies
- Business
- Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapies targeting nuclear export dysregulation for cancer and other diseases; its lead product, XPOVIO (selinexor), an oral Selective Inhibitor of Nuclear Export (SINE) compound, is approved by the FDA, European Commission, UK Medicines and Healthcare products Regulatory Agency, and Israeli Ministry of Health for multiple myeloma and diffuse large B-cell lymphoma in combination with other agents, and marketed as NEXPOVIO in Europe and the UK; the company advances a pipeline of SINE compounds including eltanexor and four clinical-stage drug candidates for hematologic malignancies and solid tumors such as endometrial cancer and myelofibrosis. Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm maintains operations across the United States, Europe (with presence in Switzerland and Germany), Israel, and China, serving oncology patients through commercial activities, clinical trials, and patient support programs like KaryForward. Recent developments include significant refinancing transactions in May 2024 with HealthCare Royalty and convertible note holders, comprising a $100 million senior secured term loan and amended royalty agreements extending debt maturities to 2028-2029 to fund Phase 3 readouts expected in 2025; a collaboration with Bristol Myers Squibb to evaluate selinexor with mezigdomide in relapsed/refractory multiple myeloma; and Q3 2025 U.S. net product revenue of $32 million for XPOVIO, up 8.5% year-over-year, alongside ongoing inducement grants under its 2022 stock plan.
Company News
Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Reviewing Alpha Cognition (NASDAQ:ACOG) & Karyopharm Therapeutics (NASDAQ:KPTI)
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis
Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI
Karyopharm Therapeutics Inc. (KPTI) Q2 2026 Earnings Call Transcript
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI
Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Beats Revenue Estimates
Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI
Karyopharm to Report Second Quarter 2026 Financial Results on August 13, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI
Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Plans to Submit sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway
Karyopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer